

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/031380 A9

(43) International Publication Date
09 March 2023 (09.03.2023)

(51) International Patent Classification:

A61K 38/26 (2006.01) A61P 3/04 (2006.01)
A61K 38/00 (2006.01) A61P 5/48 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2022/074420

(48) Date of publication of this corrected version:

22 February 2024 (22.02.2024)

(22) International Filing Date:

02 September 2022 (02.09.2022)

(15) Information about Correction:

see Notice of 22 February 2024 (22.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21194879.9 03 September 2021 (03.09.2021) EP
22160234.5 04 March 2022 (04.03.2022) EP

(71) Applicant: ZEALAND PHARMA A/S [DK/DK]; Sydmarken 11, 2860 Soborg (DK).

(72) Inventor: AGERSNAP, Mikkel Askjær; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Soborg (DK).

(74) Agent: MILTON, Tamara; D Young & Co LLP, 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DOSAGE REGIME

(57) Abstract: The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.



WO 2023/031380 A9